

**Submitted by:** Ligen Liu

**Title:** Efficacy and Safety of R-PAD regimen in Patients with Severe Idiopathic multicentric Castleman disease Castleman Disease: A Retrospective Case Series

**Author:** Ligen Liu, Lu Yingting, Yin Chunrong, Zhao Limin, Jiang Xuwei, Zhang Tinghua, Zhang Zhizhi, Zhou Xiang, Chang Li, Zhu Xinying, Du Chao, Yang Li,

**Objective:** To report the efficacy and safety of R-PAD regimen in four cases of patients with idiopathic multicentric Castleman disease (iMCD).

**Method:** The clinical data of the four cases of patients met the diagnostic criteria of severe iMCD were collected, the efficacy and safety of R-PAD regimen were analyzed. The detail of R-PAD regimen is as follow: Rituximab 375mg/m<sup>2</sup> d1; Bortezomib 1.3mg/m<sup>2</sup> d1, 8, 15; Liposomal adriamycin 15mg/m<sup>2</sup> d1; Dexamethasone 20mg d1-4, 9-12, 17-20. Four weeks as a course, total 4-6 courses were administered.

**Results:** Total 4 cases were enrolled, 3 female and 1 male. The median age was 45 years-old. One case was with TAFRO, 1 case idiopathic plasmacytic lymphadenopathy, 1 case NOS and 1 NOS with hemophagocytic lymphohistiocytosis. The complete remission rate were 100%, and no 3 grade above adverse events were found.

**Conclusions:** R-PAD regimen could be applied in the treatment of patients with severe iMCD.